前置血管筛查策略:决策与成本效果分析
本研究构建决策分析模型,比较单胎妊娠前置血管产前诊断的四种筛查策略:不筛查、超声指征筛查、仅体外受精(IVF)妊娠筛查和普遍筛查。结果显示,IVF妊娠筛查最具成本效果,增量成本效果比为29186.50美元/质量调整生命年;超声指征筛查次之,为56096.77美元/质量调整生命年。两种策略均低于100000美元/质量调整生命年的支付意愿阈值,作者认为两者均可适用于临床实践。
要点
- IVF妊娠筛查的增量成本效果比为29186.50美元/质量调整生命年,最具成本效果。
- 超声指征筛查的增量成本效果比为56096.77美元/质量调整生命年,次之。
- 两种筛查策略均低于100000美元/质量调整生命年的支付意愿阈值,作者认为均可适用于临床实践。
核心结论
- 在基线假设下,经阴道超声筛查前置血管在IVF妊娠中实施最具成本效果。
- IVF筛查和超声指征筛查两种策略均落在当代支付意愿阈值内,作者认为两者均可适用于临床实践。
研究设计与样本
- 构建决策分析模型,比较单胎妊娠前置血管的四种经阴道筛查策略:不筛查、超声指征筛查、仅IVF妊娠筛查和普遍筛查,筛查均在中孕期超声时进行。
- 超声指征筛查定义为:常规解剖超声检查时发现低置胎盘、边缘性或帆状脐带插入、双叶或副叶胎盘等与前置血管风险增加相关的超声征象之一时,行经阴道超声检查。
- 主要结局为每质量调整生命年(QALY)的成本(美元),从医疗系统角度分析,支付意愿阈值选为100000美元/QALY,并行单因素和多因素敏感性分析(蒙特卡洛模拟)。
主要发现
- IVF妊娠筛查最具成本效果,增量成本效果比(ICER)为29186.50美元/QALY。
- 超声指征筛查为第二具成本效果策略,ICER为56096.77美元/QALY。
- 上述数据在所有单因素和多因素敏感性分析中均稳健。
关键数值与推荐
- 支付意愿阈值:100000美元/QALY。
- IVF妊娠筛查ICER:29186.50美元/QALY。
- 超声指征筛查ICER:56096.77美元/QALY。
临床怎么用
- 作者认为,在基线假设下经阴道超声筛查前置血管在IVF妊娠中实施最具成本效果。
- 作者认为,IVF筛查和超声指征筛查两种策略均落在当代支付意愿阈值内,均可适用于临床实践。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To perform a decision and cost-effectiveness analysis comparing four screening strategies for the antenatal diagnosis of vasa previa in singleton pregnancies. METHODS: A decision-analytic model was constructed comparing vasa previa screening strategies. Published probabilities and costs were applied to four transvaginal screening scenarios that were carried out at the time of mid-trimester ultrasound: no screening, ultrasound-indicated screening, screening only pregnancies conceived by in-vitro fertilization (IVF) and universal screening. Ultrasound-indicated screening was defined as performing transvaginal ultrasound at the time of the routine anatomy ultrasound scan in response to one of the following sonographic findings associated with an increased risk of vasa previa: low-lying placenta, marginal or velamentous cord insertion or bilobed or succenturiate lobed placenta. The primary outcome was cost per quality-adjusted life year (QALY) in US$. The analysis was performed from a healthcare system perspective with a willingness-to-pay threshold of $100 000 per QALY selected. One-way and multivariate sensitivity analysis (Monte-Carlo simulation) was performed. RESULTS: This decision-analytic model demonstrated that screening pregnancies conceived by IVF was the most cost-effective strategy, with an incremental cost effectiveness ratio (ICER) of $29186.50/QALY. Ultrasound-indicated screening was the second most cost-effective, with an ICER of $56096.77/QALY. These data were robust to all one-way and multivariate sensitivity analyses performed. CONCLUSIONS: Within the baseline assumptions, transvaginal ultrasound screening for vasa previa appears to be most cost-effective when performed among IVF pregnancies. However, both IVF and ultrasound-indicated screening strategies fall within contemporary willingness-to-pay thresholds, suggesting that both strategies may be appropriate to apply in clinical practice. Copyright © 2018 ISUOG. Published by John Wiley & Sons Ltd.
引用
- Sinkey RG, Odibo AO. Vasa previa screening strategies: decision and cost-effectiveness analysis. Ultrasound Obstet Gynecol. 2018. PMID: 29786153. doi:10.1002/uog.19098
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。